Table 1.
Baseline clinico-pathological data (n=106).
| Group A (bupivacaine) (n=54) | Group B (placebo) (n=52) | ||
|---|---|---|---|
| Age (years)* | 58.8 (30.6–81.7) | 60.1 (24.8–83) | |
| Body weight (kg)* | 70 (50–105) | 71 (50–110) | |
| BMI (kg/m2)* | 27.0 (19–39) | 26.7 (18.4–39.1) | |
| ASA | I | 9 | 9 |
| II | 33 | 30 | |
| III | 12 | 13 | |
| cTNM | I | 13 | 11 |
| II | 26 | 24 | |
| IIIA | 15 | 17 | |
| pTNM | I | 14 | 16 |
| II | 23 | 21 | |
| IIIA | 17 | 15 | |
| Duration of operation (min)* | 75 (32–168) | 80 (37–185) | |
| Duration of anesthesia (min)* | 110 (65–190) | 103.5 (65–210) | |
| Theatre time (min)* | 135 (80–240) | 135 (50–225) | |
| Hospital stay (day)* | 1.0 (1–5) | 2.0 (1–6) | |
*
Values are median (range);
BMI – body mass index; ASA – anesthesia risk according to American Society of Anesthesiologists; cTNM – clinical classification of malignant tumors according to UICC(Sobin and Wittekind, 2002) [28]; pTNM – histopathological classification of malignant tumors according to UICC (Sobin and Wittekind, 2002) [28].